Key Takeaways
- Hamilton Health Sciences researchers are studying DNase-I as a potential intravenous therapy for patients with sepsis.
- The research examines whether breaking down excess DNA in the bloodstream could help reduce dangerous clotting.
- Hamilton Health Sciences describes the approach as a world-first clinical study.
Researchers Investigate DNase-I for Sepsis
DNase-I is an enzyme that breaks down DNA.
In sepsis, researchers are interested in excess DNA circulating in the bloodstream and its potential connection with dangerous clotting.
The Hamilton research team investigated whether administering DNase-I intravenously could break down this excess DNA and potentially reduce clotting-related complications associated with sepsis.
The study was therefore focused on understanding whether targeting circulating DNA could provide another potential treatment approach for patients experiencing severe infection.
What Is Sepsis?
Sepsis is a serious condition that can develop when the body's response to an infection causes widespread problems affecting normal body functions.
The condition can involve complex changes throughout the body, including processes related to inflammation and blood clotting.
Researchers continue to investigate different approaches to understanding and treating these complications.
The Hamilton Health Sciences study focused specifically on the role of DNA circulating in the bloodstream and whether an enzyme capable of breaking down DNA could influence the clotting process.
How the Experimental Approach Works
The research involved testing DNase-I as an intravenous therapy.
The basic research question was whether delivering the enzyme into the bloodstream can break down excess DNA that may be contributing to dangerous clot formation.
Rather than treating sepsis by targeting the infection alone, this research examined another part of the body's response to severe infection.
The Phase 1 study was designed to investigate whether this biological mechanism could be safely and feasibly targeted in patients with sepsis.
Study Led by Hamilton Researchers
The research was led by Dr. Patricia Liaw and Dr. Alison Fox-Robichaud at Hamilton Health Sciences.
Their work focuses on understanding the biological processes involved in sepsis and investigating whether DNase-I could have a therapeutic role.
Hamilton Health Sciences says the approach had never previously been attempted anywhere in the world.
Why DNA Matters in the Research
DNA is normally contained within cells, but damaged or dying cells can release DNA into the bloodstream.
The researchers investigated the potential effects of excess circulating DNA during sepsis.
Their approach is based on the possibility that breaking down this DNA could influence processes involved in abnormal clotting.
The study was designed to investigate this possibility rather than establish that DNase-I will ultimately become an effective sepsis treatment.
A New Direction for Sepsis Research
Sepsis can involve multiple biological processes occurring at the same time, making treatment challenging.
The Hamilton study focused on one specific mechanism involving circulating DNA and clotting.
If further research provides useful evidence, it could contribute to a better understanding of how these processes interact during severe infection.
However, the Phase 1 study does not establish that DNase-I is an effective treatment for sepsis.
TwikUp's Perspective
The importance of this research lies in the specific biological question it is attempting to answer.
Instead of assuming that DNase-I will treat sepsis, the study tested whether breaking down excess DNA in the bloodstream can influence dangerous clotting associated with the condition.
The world-first nature of the research also means that its findings could provide new evidence about this particular treatment strategy.
At the same time, it is important to distinguish a research hypothesis from an established treatment. The study does not yet demonstrate that DNase-I is an effective treatment for sepsis.
For patients and families, the most meaningful development will therefore be the evidence produced by the research, including whether the approach is safe, practical and beneficial.
What Happens Next?
The Phase 1 trial ran from 2022 to early 2026. Hamilton Health Sciences says the researchers have applied for Canadian Institutes of Health Research funding for a larger Phase 2 study at six hospitals across Canada.
That study would help determine whether targeting excess circulating DNA can influence dangerous clotting and whether the approach warrants further investigation.
Until further research findings are available, DNase-I should be understood as an investigational approach rather than an established treatment for sepsis.